ANXA2
ATC code L01
AUNP12
Abagovomab
Abdominal pain
Abemaciclib
Abituzumab
Abrilumab
Acalabrutinib
Acute kidney injury
Adagrasib
Adalimumab
Adecatumumab
Adipotide
Adrenal insufficiency
Adverse effect
Afatinib
Afelimomab
Aflibercept
Alectinib
Alemtuzumab
Alkaline phosphatase
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Andecaliximab
Anemia
Anifrolumab
Anrukinzumab
Anti-cancer medication
Antigen
Antineoplastic
Apolizumab
Asciminib
Ascites
Ascrinvacumab
Aselizumab
Asthenia
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avapritinib
Avdoralimab
Avelumab
Axatilimab
Axitinib
BMS-202
BMS-986189
BRAF (gene)
Balstilimab
Baricitinib
Basal-cell carcinoma
Basiliximab
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Belimumab
Benralizumab
Bermekimab
Bertilimumab
Besilesomab
Bevacizumab
Bimekizumab
Binimetinib
Bivatuzumab mertansine
Bleselumab
Blinatumomab
Bosutinib
Botensilimab
Brazikumab
Breast cancer
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CA-170
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Camidanlumab tesirine
Camrelizumab
Canakinumab
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carboplatin
Carcinoma
Carlumab
Carotuximab
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Ceritinib
Certolizumab pegol
Cetuximab
Chemical formula
Chimeric antibody
Cirmtuzumab
Cisplatin
Citatuzumab bogatox
Cixutumumab
Clazakizumab
Clenoliximab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Colitis
Colorectal cancer
Committee for Medicinal Products for Human Use
Complementarity-determining region
Conatumumab
Copanlisib
Cosibelimab
Crizanlizumab
Crizotinib
Cyst
DNA mismatch repair
Dabrafenib
Dacetuzumab
Daclizumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Dermatology
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab (data page)
Drozitumab
DrugBank
Drug class
Drug nomenclature
Drugs.com
Duligotumab
Dupilumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Eculizumab
Edrecolomab
Efalizumab
Eldelumab
Elotuzumab
Elranatamab
Elsilimomab
Emactuzumab
Emapalumab
Emibetuzumab
Encorafenib
Endocrine disease
Endometrial cancer
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
Epratuzumab
ErbB
Erdafitinib
Erlizumab
Erlotinib
Ertumaxomab
Etaracizumab
Etrolizumab
European Medicines Agency
Everolimus
Exotoxin
Faralimomab
Farletuzumab
Fatigue
Fedratinib
Fever
Fezakinumab
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Flanvotumab
Fletikumab
Flotetuzumab
Fontolizumab
Food and Drug Administration
Fresolimumab
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Galiximab
Ganitumab
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Gevokizumab
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
Golimumab
Gomiliximab
Guselkumab
Gynecologic oncology
HER2/neu
Half-life
Hdl (identifier)
Hedgehog signaling pathway
Hepatitis
Hodgkin lymphoma
Humanized
Humanized antibody
Hypophysitis
Hypothyroidism
ISSN (identifier)
Ianalumab
Ibalizumab
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Immune-mediated
Immune system
Immunoglobulin G
Immunosuppression
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Inebilizumab
Infigratinib
Infliximab
Inolimomab
Inotuzumab ozogamicin
Interleukin
Interleukin 2
International nonproprietary name
Intetumumab
Intravenous
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Istiratumab
Itolizumab
Ixekizumab
Janus kinase
Jaundice
KEGG
KN035
KRAS
Keliximab
Labetuzumab
Lampalizumab
Lanadelumab
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Lemalesomab
Lenvatinib
Lenzilumab
Lerdelimumab
Lesion
Lestaurtinib
Letolizumab
Leukemia
Lexatumumab
Lifastuzumab vedotin
Ligelizumab
Lilotomab
Lintuzumab
Lirentelimab
Lirilumab
List of withdrawn drugs
Liver function tests
Lokivetmab
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lulizumab pegol
Lumiliximab
Lumretuzumab
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Mapatumumab
Margetuximab
Masitinib
Maslimomab
Matuzumab
Mavrilimumab
Medicaid
MedlinePlus
Mepolizumab
Metelimumab
Microsatellite instability
Midostaurin
Milatuzumab
Minretumomab
Mirikizumab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibodies
Monoclonal antibody
Monoclonal antibody therapy
Monotherapy
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Myeloid
Nacolomab tafenatox
Namilumab
Naptumomab estafenatox
Narnatumab
Natalizumab
Naxitamab
Necitumumab
Neoplasm
Nephritis
Neratinib
Nerelimomab
Nesvacumab
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Nivolumab/relatlimab
Non-receptor tyrosine kinase
Non-small-cell lung carcinoma
Obinutuzumab
Ocaratuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Oleclumab
Olmutinib
Olokizumab
Omalizumab
Onartuzumab
Ontamalimab
Ontuxizumab
Open-label trial
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otelixizumab
Otlertuzumab
Oxaliplatin
Oxelumab
Ozoralizumab
PD-1 and PD-L1 inhibitors
PD-L1
PMC (identifier)
PMID (identifier)
PRO 140
Paclitaxel
Pacritinib
Palbociclib
Pamrevlumab
Panitumumab
Parsaclisib
Parsatuzumab
Pascolizumab
Pateclizumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Perakizumab
Pertuzumab
Pexelizumab
Pexidartinib
Phases of clinical research
Pi3K inhibitor
Pidilizumab
Pinatuzumab vedotin
Pirtobrutinib
Placebo-controlled trial
Placulumab
Platelet-derived growth factor receptor
Platinum-based antineoplastic
Plozalizumab
Pneumonitis
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Priliximab
Pritumumab
Proapoptotic
Programmed cell death protein 1
Programmed death-ligand 1
Prohibitin
Prolgolimab
PubChem
Public domain
Quilizumab
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radotinib
Radretumab
Ramucirumab
Ravulizumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Relatlimab
Renal cell carcinoma
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Risankizumab
Rituximab
Robatumumab
Rociletinib
Rontalizumab
Rosmantuzumab
Route of administration
Rovalpituzumab tesirine
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Samalizumab
Sarcoma
Sarilumab
Satralizumab
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Sepsis
Seribantumab
Serplulimab
Shortness of breath
Sibrotuzumab
Sifalimumab
Siltuximab
Simtuzumab